Comparison of KRAS Mutation, Microsatellite Instability and Histomorphologic Features in Metastatic Colorectal Carcinomas: Single Centre Experience

Gizem Ay Haldız; Ümit Çobanoğlu

Makale detayları

Comparison of KRAS Mutation, Microsatellite Instability and Histomorphologic Features in Metastatic Colorectal Carcinomas: Single Centre Experience

Yazarlar:

Gizem Ay Haldız | Ümit Çobanoğlu

Yayıncı:

Kafkas University

Ana Başlıklar:

Patoloji

Dergi:

Kafkas Tıp Bilimleri Dergisi Vol.14 Issue 2, pp.131-137

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326444

pISSN:

2146-2631

Anahtar kelimeler:

Özet:

 Aim: Microsatellite instability MSI and KRAS mutations change colorectal carcinoma CRC treatment protocols. Advanced examinations such as immunohistochemistry and polymerase chain reaction PCR are required to determine MSI and KRAS mutations. On the other hand, Crohn-like lymphoid reaction CLR, tumor-infiltrating lymphocytes TIL, tumor budding TB, and desmoplastic response DR are histomorphologic features that can be determined only with routine hematoxylin-eosin HE sections. Our study aimed to evaluate relationships between MSI, KRAS mutations, and histomorphologic features. It was thought that the relationships to be determined may be useful in predicting KRAS mutations and MSI by evaluating only HE sections. Material and Method: One hundred nine metastatic CRC cases were reviewed retrospectively. Polymerase chain reaction results were obtained from the molecular pathology report archive and performed on all cases for KRAS mutation detection upon clinical request during routine pathologic examinations. MLH1, MSH2, MSH6, and PMS2 immunohistochemistry, performed on 70 cases for MSI interpretation upon clinical request during routine pathological examinations, was re-evaluated for standardization. Routine HE sections with tumors were examined for CLR, TIL, TB, and DR according to study-specific criteria. Results: KRAS mutations were found in 35.77 39109, MSI in 24.28 1770, CLR in 32.11 35109, TIL in 44.95 49109, TB in 73.39 80109, DR in 84.40 92109 of the cases. CLR, TIL, DR, and KRAS mutations were higher in microsatellite stable MSS cases, and TB was higher in MSI cases. Crohn-like lymphoid reaction, TIL, DR, and MSI were higher in KRAS wild cases, and TB in KRAS mutant cases. Only the MSS-DR correlation was statistically significant. Conclusion: The MSS-DR correlation was statistically significant in our study. However, desmoplasia was determined in 92.45 of MSS cases, and was also determined in 58.82 of MSI cases. Because DR is an expected feature in tumor stroma, its guidance in terms of MSI was limited. Also, no significant relationship was found between MSI and DR in Turkish or English literature. In our study, histomorphologic features were insufficient to predict MSI and KRAS mutations. It is vital to immediately refer patients with metastases evaluated in centers without immunohistochemistry and PCR facilities to an advanced center for MSI and KRAS mutation determination diagnosing CRC, especially for treatment selection.

 Aim: Microsatellite instability MSI and KRAS mutations change colorectal carcinoma CRC treatment protocols. Advanced examinations such as immunohistochemistry and polymerase chain reaction PCR are required to determine MSI and KRAS mutations. On the other hand, Crohn-like lymphoid reaction CLR, tumor-infiltrating lymphocytes TIL, tumor budding TB, and desmoplastic response DR are histomorphologic features that can be determined only with routine hematoxylin-eosin HE sections. Our study aimed to evaluate relationships between MSI, KRAS mutations, and histomorphologic features. It was thought that the relationships to be determined may be useful in predicting KRAS mutations and MSI by evaluating only HE sections. Material and Method: One hundred nine metastatic CRC cases were reviewed retrospectively. Polymerase chain reaction results were obtained from the molecular pathology report archive and performed on all cases for KRAS mutation detection upon clinical request during routine pathologic examinations. MLH1, MSH2, MSH6, and PMS2 immunohistochemistry, performed on 70 cases for MSI interpretation upon clinical request during routine pathological examinations, was re-evaluated for standardization. Routine HE sections with tumors were examined for CLR, TIL, TB, and DR according to study-specific criteria. Results: KRAS mutations were found in 35.77 39109, MSI in 24.28 1770, CLR in 32.11 35109, TIL in 44.95 49109, TB in 73.39 80109, DR in 84.40 92109 of the cases. CLR, TIL, DR, and KRAS mutations were higher in microsatellite stable MSS cases, and TB was higher in MSI cases. Crohn-like lymphoid reaction, TIL, DR, and MSI were higher in KRAS wild cases, and TB in KRAS mutant cases. Only the MSS-DR correlation was statistically significant. Conclusion: The MSS-DR correlation was statistically significant in our study. However, desmoplasia was determined in 92.45 of MSS cases, and was also determined in 58.82 of MSI cases. Because DR is an expected feature in tumor stroma, its guidance in terms of MSI was limited. Also, no significant relationship was found between MSI and DR in Turkish or English literature. In our study, histomorphologic features were insufficient to predict MSI and KRAS mutations. It is vital to immediately refer patients with metastases evaluated in centers without immunohistochemistry and PCR facilities to an advanced center for MSI and KRAS mutation determination diagnosing CRC, especially for treatment selection.

 Aim: Microsatellite instability MSI and KRAS mutations change colorectal carcinoma CRC treatment protocols. Advanced examinations such as immunohistochemistry and polymerase chain reaction PCR are required to determine MSI and KRAS mutations. On the other hand, Crohn-like lymphoid reaction CLR, tumor-infiltrating lymphocytes TIL, tumor budding TB, and desmoplastic response DR are histomorphologic features that can be determined only with routine hematoxylin-eosin HE sections. Our study aimed to evaluate relationships between MSI, KRAS mutations, and histomorphologic features. It was thought that the relationships to be determined may be useful in predicting KRAS mutations and MSI by evaluating only HE sections. Material and Method: One hundred nine metastatic CRC cases were reviewed retrospectively. Polymerase chain reaction results were obtained from the molecular pathology report archive and performed on all cases for KRAS mutation detection upon clinical request during routine pathologic examinations. MLH1, MSH2, MSH6, and PMS2 immunohistochemistry, performed on 70 cases for MSI interpretation upon clinical request during routine pathological examinations, was re-evaluated for standardization. Routine HE sections with tumors were examined for CLR, TIL, TB, and DR according to study-specific criteria. Results: KRAS mutations were found in 35.77 39109, MSI in 24.28 1770, CLR in 32.11 35109, TIL in 44.95 49109, TB in 73.39 80109, DR in 84.40 92109 of the cases. CLR, TIL, DR, and KRAS mutations were higher in microsatellite stable MSS cases, and TB was higher in MSI cases. Crohn-like lymphoid reaction, TIL, DR, and MSI were higher in KRAS wild cases, and TB in KRAS mutant cases. Only the MSS-DR correlation was statistically significant. Conclusion: The MSS-DR correlation was statistically significant in our study. However, desmoplasia was determined in 92.45 of MSS cases, and was also determined in 58.82 of MSI cases. Because DR is an expected feature in tumor stroma, its guidance in terms of MSI was limited. Also, no significant relationship was found between MSI and DR in Turkish or English literature. In our study, histomorphologic features were insufficient to predict MSI and KRAS mutations. It is vital to immediately refer patients with metastases evaluated in centers without immunohistochemistry and PCR facilities to an advanced center for MSI and KRAS mutation determination diagnosing CRC, especially for treatment selection.

 Aim: Microsatellite instability MSI and KRAS mutations change colorectal carcinoma CRC treatment protocols. Advanced examinations such as immunohistochemistry and polymerase chain reaction PCR are required to determine MSI and KRAS mutations. On the other hand, Crohn-like lymphoid reaction CLR, tumor-infiltrating lymphocytes TIL, tumor budding TB, and desmoplastic response DR are histomorphologic features that can be determined only with routine hematoxylin-eosin HE sections. Our study aimed to evaluate relationships between MSI, KRAS mutations, and histomorphologic features. It was thought that the relationships to be determined may be useful in predicting KRAS mutations and MSI by evaluating only HE sections. Material and Method: One hundred nine metastatic CRC cases were reviewed retrospectively. Polymerase chain reaction results were obtained from the molecular pathology report archive and performed on all cases for KRAS mutation detection upon clinical request during routine pathologic examinations. MLH1, MSH2, MSH6, and PMS2 immunohistochemistry, performed on 70 cases for MSI interpretation upon clinical request during routine pathological examinations, was re-evaluated for standardization. Routine HE sections with tumors were examined for CLR, TIL, TB, and DR according to study-specific criteria. Results: KRAS mutations were found in 35.77 39109, MSI in 24.28 1770, CLR in 32.11 35109, TIL in 44.95 49109, TB in 73.39 80109, DR in 84.40 92109 of the cases. CLR, TIL, DR, and KRAS mutations were higher in microsatellite stable MSS cases, and TB was higher in MSI cases. Crohn-like lymphoid reaction, TIL, DR, and MSI were higher in KRAS wild cases, and TB in KRAS mutant cases. Only the MSS-DR correlation was statistically significant. Conclusion: The MSS-DR correlation was statistically significant in our study. However, desmoplasia was determined in 92.45 of MSS cases, and was also determined in 58.82 of MSI cases. Because DR is an expected feature in tumor stroma, its guidance in terms of MSI was limited. Also, no significant relationship was found between MSI and DR in Turkish or English literature. In our study, histomorphologic features were insufficient to predict MSI and KRAS mutations. It is vital to immediately refer patients with metastases evaluated in centers without immunohistochemistry and PCR facilities to an advanced center for MSI and KRAS mutation determination diagnosing CRC, especially for treatment selection.

Makale detayları

Comparison of KRAS Mutation, Microsatellite Instability and Histomorphologic Features in Metastatic Colorectal Carcinomas: Single Centre Experience

Yazarlar:

Gizem Ay Haldız | Ümit Çobanoğlu

Yayıncı:

Kafkas University

Ana Başlıklar:

Patoloji

Dergi:

Kafkas Tıp Bilimleri Dergisi Vol.14 Issue 2, pp.131-137

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326444

pISSN:

2146-2631

colorectal cancer;

KRAS protein;

microsatellite instability

Sayı

Makale detayları

Comparison of KRAS Mutation, Microsatellite Instability and Histomorphologic Features in Metastatic Colorectal Carcinomas: Single Centre Experience

Yazarlar: Gizem Ay Haldız | Ümit Çobanoğlu

Yayıncı: Kafkas University

Ana Başlıklar: Patoloji

Dergi: Kafkas Tıp Bilimleri Dergisi Vol.14 Issue 2, pp.131-137

Belge Tipi: Makale

Yayın Tarihi: 8/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001326444

pISSN: 2146-2631

colorectal cancer;

KRAS protein;

microsatellite instability

Sayı

Yazarlar:

Gizem Ay Haldız | Ümit Çobanoğlu

Yayıncı:

Kafkas University

Ana Başlıklar:

Patoloji

Dergi:

Kafkas Tıp Bilimleri Dergisi Vol.14 Issue 2, pp.131-137

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326444

pISSN:

2146-2631